Neuronetics Net Receivables vs Capital Surpluse Analysis
STIM Stock | USD 0.84 0.04 5.00% |
Neuronetics financial indicator trend analysis is infinitely more than just investigating Neuronetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuronetics is a good investment. Please check the relationship between Neuronetics Net Receivables and its Capital Surpluse accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.
Net Receivables vs Capital Surpluse
Net Receivables vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuronetics Net Receivables account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Neuronetics' Net Receivables and Capital Surpluse is 0.85. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Neuronetics, assuming nothing else is changed. The correlation between historical values of Neuronetics' Net Receivables and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Neuronetics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Receivables i.e., Neuronetics' Net Receivables and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.85 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Receivables
Capital Surpluse
Most indicators from Neuronetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.As of the 22nd of November 2024, Selling General Administrative is likely to drop to about 19.4 M. Issuance Of Capital Stock is expected to grow at the current pace this year
2023 | 2024 (projected) | Depreciation And Amortization | 2.0M | 1.4M | Interest Income | 4.2M | 3.3M |
Neuronetics fundamental ratios Correlations
Click cells to compare fundamentals
Neuronetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neuronetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.2M | 78.7M | 141.2M | 116.9M | 115.8M | 100.9M | |
Short Long Term Debt Total | 34.3M | 38.3M | 39.5M | 39.7M | 62.5M | 44.7M | |
Other Current Liab | 9.0M | 6.0M | 6.9M | 13.4M | 10.9M | 9.3M | |
Total Current Liabilities | 27.7M | 13.7M | 15.7M | 33.2M | 19.8M | 20.5M | |
Total Stockholder Equity | 47.9M | 25.5M | 85.2M | 57.1M | 34.2M | 35.9M | |
Other Liab | 2.1M | 1.7M | 1.5M | 829K | 746.1K | 1.2M | |
Net Tangible Assets | 46.7M | 25.5M | 85.2M | 57.1M | 65.6M | 68.9M | |
Property Plant And Equipment Net | 4.9M | 4.1M | 5.1M | 5.3M | 4.8M | 3.9M | |
Current Deferred Revenue | 2.2M | 2.0M | 2.5M | 2.0M | 1.6M | 2.2M | |
Net Debt | (41.4M) | (10.6M) | (54.6M) | (30.6M) | 2.8M | 2.9M | |
Retained Earnings | (250.1M) | (277.5M) | (308.7M) | (345.9M) | (376.1M) | (394.9M) | |
Accounts Payable | 4.6M | 3.7M | 4.3M | 2.4M | 4.8M | 3.8M | |
Cash | 75.7M | 49.0M | 94.1M | 70.3M | 59.7M | 68.7M | |
Non Current Assets Total | 11.7M | 13.6M | 25.9M | 18.1M | 22.0M | 13.4M | |
Non Currrent Assets Other | 5.1M | 7.2M | 19.1M | 11.6M | 8.6M | 7.4M | |
Other Assets | 5.6M | 12.9M | 167.1M | 9.2M | 1.0 | 0.95 | |
Long Term Debt | 19.9M | 34.6M | 35.3M | 22.8M | 59.3M | 34.0M | |
Cash And Short Term Investments | 76.6M | 50.8M | 96.3M | 71.9M | 60.6M | 69.7M | |
Net Receivables | 6.6M | 7.2M | 7.8M | 13.8M | 17.8M | 9.2M | |
Common Stock Total Equity | 177K | 186K | 191K | 273K | 314.0K | 329.6K | |
Common Stock Shares Outstanding | 18.4M | 18.8M | 25.5M | 26.9M | 28.7M | 17.5M | |
Long Term Debt Total | 30.4M | 19.9M | 34.6M | 22.8M | 26.3M | 28.2M | |
Liabilities And Stockholders Equity | 100.2M | 78.7M | 141.2M | 116.9M | 115.8M | 100.9M | |
Non Current Liabilities Total | 24.6M | 39.5M | 40.3M | 26.6M | 61.8M | 63.4M | |
Capital Surpluse | 291.9M | 297.8M | 302.8M | 402.7M | 463.1M | 238.9M | |
Inventory | 2.8M | 3.7M | 6.6M | 8.9M | 8.1M | 5.0M | |
Other Current Assets | 2.5M | 3.3M | 4.6M | 4.2M | 7.3M | 7.6M | |
Other Stockholder Equity | 297.8M | 302.8M | 393.6M | 402.7M | 410.0M | 274.4M | |
Total Liab | 52.3M | 53.2M | 56.0M | 59.8M | 81.6M | 78.2M | |
Property Plant And Equipment Gross | 4.9M | 4.1M | 5.1M | 5.3M | 7.6M | 4.3M | |
Total Current Assets | 88.5M | 65.0M | 115.3M | 98.8M | 93.8M | 87.4M | |
Common Stock | 186K | 191K | 264K | 273K | 291K | 190.6K | |
Property Plant Equipment | 4.9M | 730K | 5.1M | 2.0M | 2.3M | 2.7M | |
Net Invested Capital | 79M | 60.1M | 120.5M | 93.0M | 93.5M | 60.4M | |
Net Working Capital | 60.8M | 51.3M | 99.6M | 65.6M | 74.0M | 75.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 2.453 | Quarterly Revenue Growth (0.07) | Return On Assets (0.17) | Return On Equity (1.00) |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.